Debra Frimerman Net Worth

Debra Frimerman biography

Debra H. Frimerman has been appointed General Counsel of the Company effective February 11, 2019. Before joining Calyxt, Ms. Frimerman was Associate General Counsel for Syngenta North America, as well as acting General Counsel for Syngenta Seeds, LLC. Through her seven years at Syngenta, she provided counsel for executive leadership teams and contributed to the closing of numerous global transactions; launching new products into new markets; and developing regulatory, compliance and corporate policies. Prior to her role at Syngenta, Ms. Frimerman practiced law at Stoel Rives LLP and Lindquist & Vennum PLLP (now Ballard Spahr).

What is the salary of Debra Frimerman?

As the General Counsel of Calyxt Inc, the total compensation of Debra Frimerman at Calyxt Inc is $1,975,160. There are 2 executives at Calyxt Inc getting paid more, with James Blome having the highest compensation of $4,488,350.

How old is Debra Frimerman?

Debra Frimerman is 40, she's been the General Counsel of Calyxt Inc since 2019. There are 15 older and no younger executives at Calyxt Inc. The oldest executive at Calyxt Inc is Philippe Dumont, 68, who is the Independent Director.

What's Debra Frimerman's mailing address?

Debra's mailing address filed with the SEC is Mount Ridge Road, Roseville, Ramsey County, Minnesota, 55113-5499, United States.

Insiders trading at Calyxt Inc

Over the last 7 years, insiders at Calyxt Inc have traded over $2,578,214 worth of Calyxt Inc stock and bought 116,475 units worth $1,447,167 . The most active insiders traders include Kimberly K. Nelson, Daniel F Voytas e Yves J Ribeill. On average, Calyxt Inc executives and independent directors trade stock every 23 days with the average trade being worth of $35,853. The most recent stock trade was executed by Yves J Ribeill on 19 September 2022, trading 30,000 units of CLXT stock currently worth $7,200.

What does Calyxt Inc do?

Calyxt Inc executives and stock owners

Calyxt Inc executives and other stock owners filed with the SEC include:

• James Blome,
  Chief Executive Officer, Director
• William Koschak,
  Chief Financial Officer
• Debra Frimerman,
  General Counsel
• Kimberly Nelson,
  Independent Director
• William F. Koschak,
  Chief Financial Officer
• Dr. Travis J. Frey Ph.D.,
  Chief Technology Officer
• Daniel Voytas,
  Chief Scientific Officer
• Philippe Dumont,
  Independent Director
• Yves Ribeill,
  Chairman of the Board
• Christopher Neugent,
  Independent Director
• Anna Kozicz-Stankiewicz,
  Independent Director
• Jonathan Fassberg,
  Independent Director
• Chris Tyson,
  IR Contact Officer
• Laurent Arthaud,
  Director
• Bobby Williams,
  Director - Gene Editing
• Vince Restucci,
  Vice President of Agronomy Services
• Sarah Reiter,
  Vice President - Business Development
• Travis Frey,
  Chief Technology Officer
• Keith Blanks,
  Senior Vice President of Sales and Marketing
• Gerry Nuovo,
  Sr. VP of Bus. Devel.
• Dr. Stephen M. Bravo,
  Chief Medical Officer
• Trina Lundblad,
  Director of Communications
• Debra H. Frimerman,
  Gen. Counsel & Corp. Sec.
• Dr. Daniel F. Voytas Ph.D.,
  Founder, Chief Science Officer & Chair of Scientific Advisory Board
• Michael Allen Carr,
  Pres, CEO & Director
• Michael A. Carr,
  President and CEO
• Manoj Sahoo,
  Chief Commercial Officer
• Alain Godard,
  Director
• Bryan W.J. Corkal,
  Chief Financial Officer
• Michel Arbadji,
  Director of Business Developme
• Federico A. Tripodi,
  Chief Executive Officer
• Glenn R Bowers,
  Vice President of Breeding
• S.A. Cellectis,
  10% owner